Skip to main content
OpenTrials

Clinical trial condition

Hormone-Refractory Prostate Cancer

Explore clinical trials studying Hormone-Refractory Prostate Cancer. Study availability and eligibility vary by location and protocol.

15 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Hormone-Refractory Prostate Cancer trial results

Recruiting

Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer

NCT05997615

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +9 more
Locations
  • Investigational Site Number: 403 Palo Alto, California, United States
  • Investigational Site Number: 401 Houston, Texas, United States
  • Investigational Site number: 404 Fairfax, Virginia, United States
  • Investigational Site Number: 400 Seattle, Washington, United States
View Trial Details
Completed

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

NCT03076203

Conditions
Hormone-Refractory Prostate Cancer, Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma
Locations
  • University of Alabama Birmingham, Alabama, United States
  • University of Chicago Medical Center Chicago, Illinois, United States
  • Tulane University New Orleans, Louisiana, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
View Trial Details
Completed

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552

Conditions
Adenocarcinoma, Adnexal Diseases, Astrocytoma, +78 more
Locations
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Yale University School of Medicine New Haven, Connecticut, United States
  • Helen F. Graham Cancer Center Newark, Delaware, United States
  • MD Anderson Cancer Center Orlando (UF Health Cancer Center) Orlando, Florida, United States
View Trial Details
Completed

Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer

NCT02288936

Conditions
Hormone-Refractory Prostate Cancer
Locations
  • Hospital Universitari Son Espases Palma de Mallorca, Balearic Islands, Spain
  • Hospital Universitari Germans Trias I Pujol de Badalona Badalona, Barcelona, Spain
  • Hospital Clinic I Provincial de Barcelona Barcelona, Spain
  • Hospital Parc Taulí Barcelona, Spain
View all 16 locations
View Trial Details
Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

NCT00570700

Conditions
Adenocarcinoma of the Prostate, Genital Diseases, Genital Diseases, Male, +12 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Loma Linda University Cancer Center Loma Linda, California, United States
  • Chao Family Comprehensive Cancer Center Orange, California, United States
  • St. Joseph Hospital Orange, California, United States
View Trial Details
Completed

Study of ILX651 in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel

NCT00082134

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Arizona Clinical Research Center Tucson, Arizona, United States
  • Kansas City Cancer Centers Lenexa, Kansas, United States
  • Kansas City Cancer Centers Overland Park, Kansas, United States
  • Kansas City Cancer Centers- Central Kansas City, Missouri, United States
View Trial Details
Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00337077

Conditions
Adenocarcinoma of the Prostate, Genital Diseases, Genital Diseases, Male, +11 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Community Hospital of Monterey Peninsula Monterey, California, United States
  • Manchester Memorial Hospital Manchester, Connecticut, United States
  • Boca Raton Regional Hospital Boca Raton, Florida, United States
View all 147 locations
View Trial Details

Related conditions